Sun Pharma Advanced Research Co Ltd

Stage 3 · Topping · week 8

As of 16 Oct 2026, Sun Pharma Advanced Research Co is in Stage 3 — topping, where an uptrend loses steam, in week 8 (since 26 Aug 2026). It closed at ₹189, 32.0% below its 52-week high and above its 200-day average, which is rising. In Health Care, 40.6% of stocks are in Stage 2.

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. More about the company

₹188.6
+0.18% today
₹6,122 Cr · Mid cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Topping — the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is SPARC early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-32.0%
₹108.7 lo₹277.6 hi
32.0% below 52W high — weakening from peak
Stock is rolling over from its 52W high. Stage 3 distribution — new longs are high risk here.
Stage Maturity
Week 8
1w13w26w
Week 8 — distribution, avoid new longs
How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.
vs 200 DMA
7.4%
200 DMA: ₹175.7 · rising
Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.
Rel Volume
0.46x
vs 50-day avg
Volume spikes on down days during Stage 3 signal distribution — institutions are exiting. A clear warning to avoid new longs.
Trend Health
↓
MA20 rolling over · -1.8% vs MA50 -6.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+1.6%
3M
-19.8%
6M
+23.7%
YTD
+35.0%
1Y
+47.3%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 24w
S4 36w
S4 19w
S2 14w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S1 2w → S2 11w → S3 3w → S2 24w → S3 5w → S4 8w → S1 5w → S4 36w → S1 12w → S4 19w → S1 6w → S4 12w → S1 3w → S2 14w → S3 7w current
Total tracked: 168 weeks across 15 stage runs.
Scan Membership
Pullback Hunter
Latest: 2026-07-21
Prop Scan
Latest: 2026-07-21
Breakout Watch
Latest: 2026-05-18
56 appearances in last 60 days. First seen: 2026-05-18.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S3
Wk 8 · Vol 0.46x
2026-10-15S3
Wk 7 · Vol 0.59x
2026-10-14S3
Wk 7 · Vol 1.36x
2026-10-13S3
Wk 7 · Vol 0.71x
2026-10-12S3
Wk 7 · Vol 0.55x
2026-10-09S3
Wk 7 · Vol 0.84x
2026-10-08S3
Wk 6 · Vol 1.31x
2026-10-07S3
Wk 6 · Vol 1.11x
2026-10-06S3
Wk 6 · Vol 0.71x
2026-10-05S3
Wk 6 · Vol 0.84x
2026-10-01S3
Wk 6 · Vol 1.05x
2026-09-30S3
Wk 5 · Vol 1.34x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹197.8
200 DMA
₹175.7
52W High
₹277.6
52W Low
₹108.7
5D Low
₹184.9
Resistance levels (recent highs)
20d High
₹209.1
60d High
₹218.4
120d High
₹277.6
250d High
₹277.6
Next resistance
+10.8%
to 20d High
Ask the Market AI about SPARCAsk →
P/E (TTM)
4.6
Forward 4.0
ROE
+276.9%
Profit margin +3967.3%
About this companyHealth Care· Pharmaceuticals

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.